logo
Bearded vultures: Back from the brink

Bearded vultures: Back from the brink

CNN8 hours ago

Bearded vultures have a wing span up to 2.85 meters (9.3 feet) allowing them to hunt over 700 kilometers (435 miles) in a day. The feathers on their neck, head and torso are naturally white, but they dye them orange by covering themselves in the iron oxide-rich mud found in the mountains and highlands where they live. However, their name comes from the distinctive black tuft of feathers under their beak. Hansruedi Weyrich/Vulture Conservation Foundation
Bearded vultures are scavengers, and up to 85% of their diet is bone. Historically, they were called 'ossifrage,' derived from the Latin for 'bone breaker.' They mostly swallow bones whole, their strong stomach acid breaking them down, but if a bone is too big, they will drop it from height onto a rock to break it and expose the nutrient rich marrow inside. Hansruedi Weyrich/Vulture Conservation Foundation
While Alpine farmers no longer blame the vultures for missing sheep, or children, the birds are still threatened. Accidental poisoning through eating animal carcasses containing drugs, pathogens or steroids, collisions with power lines and wind turbines and habitat degradation have reduced the global population — which spans from western Spain to China — by as much as 29% in the last three generations. Exacerbating this problem is their slow breeding rate. A breeding pair will only lay one or two eggs a year, and even if both hatch, the stronger chick will kill its weaker sibling. Here, a bearded vulture in the wild shows off its name-sake feathers. Hansruedi Weyrich/Vulture Conservation Foundation
Initial attempts by conservationists to reintroduce the bearded vulture involved capturing birds in Afghanistan and releasing them in the Alps, but the project failed due to the difficulty in capturing and transporting the birds. However, in 1986, three birds that had been raised in captivity at a center in Austria were released successfully in the country's mountains, leading to a flurry of further releases across the Alps. The young birds are put in artificial nests on cliffs, enabling them to acclimatize to the new environment, and after 20 to 30 days they take their first flight. Young bearded vultures are known for traveling vast distances. In 2020, one bird flew 1,200 kilometers (745 miles) from Haute-Savoie in the French Alps to the Peak District in the north of England. Regardless of how far they roam, when they reach adulthood, they typically return home. Here, conservationists climb to a release site in the Bavarian Alps in June, 2021. Hansruedi Weyrich/Vulture Conservation Foundation
The Alpine population is increasing 'exponentially,' José Tavares, director of the Vulture Conservation Foundation, told CNN. Now that the population is stable, the team have started releasing genetically distinct birds to increase the diversity of the population so 'they're fully equipped to survive, even in a period of climate change.' Pictured here, a captive-bred chick at Vallcalent Specialized Breeding Unit in Spain. Hansruedi Weyrich/Vulture Conservation Foundation
While releases in the Alps are winding down as the population grows naturally, the VCF is working on 'replication and expansion' projects in Valencia and Andalucia in Spain, the Massif Central in France, and the Balkans, as well as possible projects in North Africa, said Tavares. Here, a bearded vulture is photographed among griffon vultures in the Spanish Catalan Pyrenees. William Van Hecke/Corbis/Getty Images
Another conservation project in the Maloti-Drakensberg mountains of Lesotho and South Africa is working to save the last bearded vultures in the southern hemisphere. The Bearded Vulture Recovery Program did not have a captive breeding program when it started, so instead, when a vulture lays two eggs, the team takes the second egg from the nest, which would be killed by its sibling anyway, and raises the chicks in captivity before releasing them. They are now raising 27 birds in captivity and aim to reach 150 breeding pairs in the wild. With these global conservation efforts, there is hope that bearded vultures will continue to soar across mountains all over the world. Pictured here, a bearded vulture in flight in Giant's Castle Game Reserve, South Africa. Education Images/Universal Images

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Light-powered robot swarms may replace antibiotics for tough sinus infections
Light-powered robot swarms may replace antibiotics for tough sinus infections

Yahoo

time3 hours ago

  • Yahoo

Light-powered robot swarms may replace antibiotics for tough sinus infections

Swarms of microrobots have been designed to help get rid of bacterial sinus infections. After completing the task, these tiny robots can be easily expelled from the nose. Interestingly, these tiny, light-activated robots are reportedly as small as a "dust speck." These are called CBMRs (copper single–atom–loaded bismuth oxoiodide photocatalytic microrobots). The China-Hong Kong team has successfully inserted newly developed microrobots into animal sinuses during preclinical trials to treat bacterial infections. 'Our proposed microrobotic therapeutic platform offers the advantages of noninvasiveness, minimal resistance, and drug-free intervention,' the researchers from Guangxi University, Shenzhen University, and the Chinese University of Hong Kong stated. Chronic sinusitis treatments have long been problematic, offering a choice between invasive surgery and often ineffective drug delivery. In the past, magnetic microrobots have been created, but it's tough for them to move through inflamed areas in the body that are clogged with thick pus and cellular debris. Driven by the limitations of current treatments, scientists, under the leadership of Haidong Yu, engineered these light-activated microbots to combat deep-seated bacterial infections in the sinuses effectively. Researchers first created tiny magnetic particles (CBMRs) containing antibacterial copper. They then built a special magnetically guided optical fiber to both control the movement of these microrobots and shine visible light on them. Here's how these tiny bots work. Reportedly, microrobot swarms are injected into the sinus cavity through the nostril duct. A magnetic field can precisely steer them, navigating even the most inflamed and viscous sinus environments directly to the infection site. 'They constructed a magnetically guided optical fiber that could coordinate the movements of CBMR swarms and illuminate them with visible light. Under a magnetic field, CBMRs exert collective mechanical forces that disrupt bacterial cell walls,' the team explained. Once in place, this designed optical fiber shines visible light, activating the CBMRs, and causing them to release heat for better movement. When activated by light, these microrobots perform two key functions: they exert collective mechanical forces to break apart robust bacterial biofilms. Moreover, they generate antibacterial reactive oxygen species (ROS), which are free radicals that effectively kill the now-exposed bacteria. The team tested the microbots on animal models. In preclinical trials, these microrobots proved highly effective: they eliminated bacterial biofilms in lab settings and successfully cleared infections in rabbit models of sinusitis. Moreover, CBMRs were shown to effectively clear bacteria from pig sinuses outside of a living body. Remarkably, these positive outcomes occurred without tissue damage or side effects, and the microrobots were even naturally expelled from the nose. The team says this new approach comes with various benefits. As it's non-invasive, the technique eliminates the need for complex surgeries. Moreover, it promotes minimal resistance since it doesn't depend on traditional drugs, thereby reducing the risk of antibiotic resistance. Essentially, it offers a novel, drug-free intervention for fighting infections. 'The authors propose that their approach could be applied to treat other sinus-related diseases,' the press release noted. The findings were published in the journal Science Robotics.

Mediterranean Diet Could Protect Against a Common Form of Liver Disease
Mediterranean Diet Could Protect Against a Common Form of Liver Disease

Yahoo

time4 hours ago

  • Yahoo

Mediterranean Diet Could Protect Against a Common Form of Liver Disease

The Mediterranean diet, high in plants and low on meat and dairy, has been linked to a host of health benefits – including longer life and lower cancer risk. Now we can add another benefit to the list, according to a new study: protection against metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD affects around one in three of us worldwide, and occurs when too much fat builds up in the liver. It can lead to inflammation, cancer, and fibrosis, and is closely linked to other issues such as type 2 diabetes and obesity. The new review study, led by a team from the University of Rovira i Virgili in Spain, looked at 13 previous trials and studies involving 926 participants and a variety of diet approaches. Each of the reviewed trials involved people with MASLD. It was the Mediterranean diet that stood out in terms of its health benefits, with intermittent fasting also making a notable difference in terms of numerous key health markers. Several signs of MASLD in the liver were reduced by these diets. "This review suggests that Mediterranean diet and intermittent fasting-based strategies may reduce body weight, improve glycemic control, and lower inflammation, with potential benefits for hepatic [liver] function," write the researchers in their published paper. "Further long-term studies are needed to confirm these effects and underlying mechanisms, which will allow for the optimization of protocols and ensure their safety in MASLD." It's important to note that while all the reviewed studies involved people with MASLD, the disease wasn't their primary focus. The researchers here are doing some joining of the dots when it comes to how certain biomarkers (such as glycemic control and inflammation levels) might link to MASLD outcomes. In theory, the benefits that the research shows for the Mediterranean diet and intermittent fasting should reduce the severity of MASLD, or stop it from developing in the first place. But as the researchers acknowledge, we'll need longer-term studies looking at disease progression over time to be more sure. "Despite the limited data on liver function outcomes, the results of this review provided early indication of the promising potential of Mediterranean diet-based interventions," write the researchers. The Mediterranean diet emphasizes fruits, vegetables, whole grains, nuts, olive oil, fish, and poultry, while minimizing sugar, red meat, and processed foods. Its name comes from its region of origin, particularly countries like Greece and Italy. It's an approach to eating that's been around for thousands of years, and which has previously been linked to reduced severity of fatty liver disease – though it's important not to assume direct cause and effect, with so many variables involved. What's clear is that the Mediterranean diet is very good for us, and can keep our bodies functioning in a healthier way for a longer period of time. Scientists are still exploring how exactly it works, but it seems the effects extend to conditions in the liver too. "MASLD is a complex condition with many factors implicated in its risk/development, including nutrition and immune-metabolic health status," write the researchers. "Consequently, investigating the influence and effectiveness of dietary patterns in improving hepatic function, along with immuno-metabolism, can be important in MASLD management." The research has been published in Nutrients. Disordered Eating vs Eating Disorders: What's The Difference? Parkinson's Disease Might Not Start in The Brain, Study Finds These Common Drugs Can Make Coping With Heat Even Harder

Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer

Yahoo

time4 hours ago

  • Yahoo

Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer

At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone SHANGHAI & CAMBRIDGE, Mass., June 30, 2025--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis. Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS as compared to placebo plus chemotherapy in people living with unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer with FGFR2b overexpression and who are non-HER2 positive. FGFR2b overexpression was defined as 2+/3+ staining in ≥10% of tumor cells by centrally performed immunohistochemistry (IHC) testing. Gastric cancer is the fifth leading cause of cancer-related death worldwide, with nearly one million new cases and over 650,000 deaths globally each year 1, highlighting a critical unmet medical need. In China, there are over 350,000 new cases each year. The disease is associated with a poor prognosis, particularly in advanced stages where the five-year survival rate is less than 10%. There are currently no approved therapies specifically targeting FGFR2b overexpression in gastric cancer in China. "Bemarituzumab is the first FGFR2b inhibitor to demonstrate a statistically and clinically significant overall survival benefit in a randomized Phase 3 trial for the first-line treatment of FGFR2b-positive gastric cancer," said Dr. Rafael Amado, M.D., President, Head of Global Research and Development at Zai Lab. "The success of the global Phase 3 FORTITUDE-101 study highlights the potential of bemarituzumab to redefine the standard of care for a patient population that has faced poor outcomes with existing therapies. We are proud to have contributed meaningfully to this pivotal trial, including a substantial number of patients enrolled in China. Based on these results, and the regulatory Breakthrough Designation, we plan to move rapidly toward regulatory submission in China to bring this transformative therapy to patients as quickly as possible." The most common treatment-emergent adverse events (>25%) in patients treated with bemarituzumab plus chemotherapy were reduced visual acuity, punctate keratitis, anaemia, neutropenia, nausea, corneal epithelium defect and dry eye. While ocular events were consistent with the Phase 2 experience and observed in both arms, they occurred with greater frequency and severity in the Phase 3 bemarituzumab arm. Detailed results from the trial will be shared at a future medical meeting. Zai Lab holds the development and commercialization rights for bemarituzumab for mainland China, Hong Kong, Macau, and Taiwan. Bemarituzumab has been granted Breakthrough Therapy designation by the China Center for Drug Evaluation of the National Medical Products Administration for the treatment of FGFR2b-positive gastric and gastroesophageal junction adenocarcinoma. A Phase 3 study of bemarituzumab plus chemotherapy and nivolumab is also ongoing in patients with first-line gastric cancer, with data readout anticipated in H2 2025. About FGFR2b The FGFR2b protein (also known as fibroblast growth factor receptor 2b) is an emerging biomarker which, when overexpressed, promotes aberrant signaling leading to tumor cell proliferation.2 The FGFR2b protein is overexpressed by G/GEJ tumor cells in approximately 38% of patients with advanced G/GEJ cancer. FGFR2b protein overexpression is defined as 2+/3+ staining intensity on tumor cell membrane, as detected by immunohistochemistry (IHC) testing. In approximately 16% of patients with advanced G/GEJ cancer, FGFR2b protein overexpression is observed on ≥10% of tumor cells by IHC.3 About FORTITUDE-101 FORTITUDE-101 is a randomized, multi-center, double-blind, placebo-controlled Phase 3 study of bemarituzumab plus mFOLFOX6 versus placebo plus mFOLFOX6 as first-line therapy in advanced G/GEJ cancer with FGFR2b overexpression. The FORTITUDE-101 trial spanned 300 sites across 37 countries, with 547 patients enrolled. The primary outcome measure of the trial is overall survival in patients with FGFR2b ≥10% 2+/3+ tumor cell staining. Key secondary outcome measures include progression-free survival and overall response rate. Candidates were excluded from the trial if they were known to be human epidermal growth factor receptor 2 (HER2) positive. FORTITUDE-101 included more comprehensive ocular-related monitoring than previous studies of bemarituzumab. About Gastric Cancer in China Gastric cancer is the fifth most common cancer worldwide, while China bears one of the highest gastric cancer burdens in the world with an estimated 358,700 new cases and 260,400 deaths annually.4 In China, approximately 80% of gastric cancer patients are diagnosed at an advanced or metastatic stage5. For those diagnosed with Stage IV gastric cancer, the overall 5-year survival rate is less than 10%6. Patients with advanced gastric and GEJ cancer that overexpress the FGFR2b protein may be associated with poor prognosis7-10. About Zai Lab Zai Lab is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health worldwide. For additional information about Zai Lab, please visit or follow us at Zai Lab Forward Looking Statements This press release contains forward-looking statements relating to our future expectations, plans, and prospects, including, without limitation, statements regarding the prospects and plans for developing and commercializing bemarituzumab, the potential benefits of bemarituzumab, and the potential treatment of gastric and gastroesophageal junction cancer. All statements, other than statements of historical fact, included in this press release are forward-looking statements, and can be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "possible," "potential," "will," "would," and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of our clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Our SEC filings can be found on our website at and the SEC's website at REFERENCES Bray F, et al. CA Cancer J Clin. 2024;74(3);229-263 Wainberg ZA, et al. Lancet Oncol. 2022;23(11):1430-40 Rha SY, et al. JCO Precis Oncol. 2025; 9 (e2400710). DOI:10.1200/PO-24-00710 Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. Health Commission of The People's Republic Of China N. National guidelines for diagnosis and treatment of gastric cancer 2022 in China (English version). Chin J Cancer Res. 2022;34(3):207-237. Li HQ, Zhang H, Zhang HJ, Wang YX, Wang XB, Hou HF. Survival of gastric cancer in China from 2000 to 2022: A nationwide systematic review of hospital-based studies. J Glob Health 2022;12:11014. Catenacci D, et al. Presented at American Society of Clinical Oncology; June 4-8, 2021; Online Virtual Scientific Program. Abstract 4010. Ahn S, et al. Mod Pathol. 2016;29:1095-1103. Ishiwata T. Front Biosci (Landmark Ed). 2018;23:626-639. Wainberg ZA, et al. Lancet Oncol. 2022;23:1430-1440. View source version on Contacts For more information, please contact: Investor Relations: Christine Chiou / Lina Zhang+1 (917) 886-6929 / +86 136 8257 / Media: Shaun Maccoun / Xiaoyu Chen+1 (857) 270-8854 / +86 185 0015 / Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store